Corbus Pharmaceuticals Holding
$ 7.63
2.83%
24 Feb - close price
- Market Cap 133,930,000 USD
- Current Price $ 7.63
- High / Low $ 7.88 / 7.44
- Stock P/E N/A
- Book Value 7.35
- EPS -5.49
- Next Earning Report 2026-03-10
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.35 %
- ROE -0.56 %
- 52 Week High 20.56
- 52 Week Low 4.64
About
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of novel therapies that target the endocannabinoid system in the fields of autoimmunity, fibrosis, and cancer. The company is headquartered in Norwood, Massachusetts.
Analyst Target Price
$42.33
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-12 | 2025-08-05 | 2025-05-05 | 2025-03-10 | 2024-11-05 | 2024-08-06 | 2024-05-07 | 2024-03-12 | 2023-11-07 | 2023-08-08 | 2023-05-09 | 2023-03-07 |
| Reported EPS | -1.9 | -1.44 | -1.3914 | -0.78 | -1.15 | -0.9 | -0.83 | -1.81 | -2.05 | -2.05 | -4.24 | -2.61 |
| Estimated EPS | -1.28 | -1.23 | -1.0729 | -1.2589 | -0.95 | -1.19 | -1.09 | -2.36 | -2.06 | -3.1 | -4.09 | -2.1 |
| Surprise | -0.62 | -0.21 | -0.3185 | 0.4789 | -0.2 | 0.29 | 0.26 | 0.55 | 0.01 | 1.05 | -0.15 | -0.51 |
| Surprise Percentage | -48.4375% | -17.0732% | -29.6859% | 38.0411% | -21.0526% | 24.3697% | 23.8532% | 23.3051% | 0.4854% | 33.871% | -3.6675% | -24.2857% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-10 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -1.78 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CRBP
2026-02-18 00:56:00
This article provides an analysis of Corbus Pharmaceuticals Holdings Inc. (CRBP), highlighting weak near and mid-term sentiment despite a positive long-term outlook. It details AI-generated institutional trading strategies for various risk profiles, including position trading, momentum breakout, and risk hedging. The analysis also includes multi-timeframe signal data for support and resistance levels.
2026-02-13 00:58:21
Corbus Pharmaceuticals Holdings Inc. announced that CEO Yuval Cohen, Ph.D., will present a corporate overview and attend investor meetings at the 36th Annual Oppenheimer Healthcare Life Sciences Conference on February 25, 2026. The company, focused on oncology and obesity, will present virtually at 3:20 PM Eastern Time. Corbus's pipeline includes CRB-701, CRB-601, and CRB-913, targeting cancer and obesity.
2026-02-13 00:58:21
Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP) announced that its CEO, Yuval Cohen, Ph.D., will present a corporate overview and meet with investors at the virtual 36th Annual Oppenheimer Healthcare Life Sciences Conference on February 25, 2026. The company, focused on oncology and obesity, will highlight its diversified pipeline which includes CRB-701, CRB-601, and CRB-913.
2026-02-12 23:26:53
Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP) announced that its CEO, Yuval Cohen, Ph.D., will present a corporate overview and meet with investors at the virtual 36th Annual Oppenheimer Healthcare Life Sciences Conference on February 25, 2026. The company is a clinical-stage oncology and obesity company with a pipeline that includes CRB-701, CRB-601, and CRB-913.
2026-02-12 13:28:17
Corbus Pharmaceuticals Holdings Inc. will present a corporate overview and meet with investors at the 36th Annual Oppenheimer Healthcare Life Sciences Conference on February 25, 2026. CEO Yuval Cohen, Ph.D., will lead the virtual presentation, highlighting the company's clinical-stage oncology and obesity pipeline. The pipeline includes CRB-701 for Nectin-4 positive cancers, CRB-601 for cancer, and CRB-913 for obesity.
2026-02-12 13:28:17
Corbus Pharmaceuticals Holdings Inc. announced that its CEO, Yuval Cohen, Ph.D., will present a corporate overview and hold investor meetings at the virtual 36th Annual Oppenheimer Healthcare Life Sciences Conference on February 25, 2026. The clinical-stage company, focused on oncology and obesity, will highlight its pipeline, including CRB-701, CRB-601, and CRB-913. The presentation aims to increase visibility within the investment community and showcase the company's innovative approaches to treating serious illnesses.
